Stock FNAM EVOLUTIONARY GENOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Evolutionary Genomics, Inc.

Equities

FNAM

US30051F1012

Market Closed - OTC Markets
Other stock markets
 20:26:12 18/07/2023 BST 		5-day change 1st Jan Change
0.45 USD -25.00% Intraday chart for Evolutionary Genomics, Inc. -.--% -.--%
2023 Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
2023 Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt
CI
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding
CI
EVOLUTIONARY GENOMICS, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Evolutionary Genomics, Inc. announced that it expects to receive $1.004004 million in funding
CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)
AQ
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt
CI
Queen Mary University of London : New study pinpoints bumblebee genes that help them adapt to environmental changes
AQ
EVOLUTIONARY GENOMICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
CI
EVOLUTIONARY GENOMICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FNAM Stock
  4. News Evolutionary Genomics, Inc.